Women who received both rounds of the Pfizer-BioNTech vaccine might have a greater level of protection against COVID-19 than men who take the same action, according to a study released Wednesday.
Women 65 years and older were recorded to have higher antibody counts than men in the same age bracket, at 46% and 37%, respectively, according to data from the New England Journal of Medicine.
“Six months after receipt of the second dose of the BNT162b2 vaccine, humoral response was substantially decreased, especially among men, among persons 65 years of age or older, and among persons with immunosuppression,” the survey concluded.
HUNDREDS OF THOUSANDS OF COVID-19 TEST KITS RECALLED OVER FALSE POSITIVE CONCERNS
Women also maintained a greater number of antibodies during the highest level of antibody protection, the study reported.
Results showed that antibodies declined in men and women up to 80 days following their second shots.
The Food and Drug Administration approved booster doses of the Pfizer vaccine for people over 65 and those at risk of serious illness on Sept. 22.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
The study was conducted with more than 4,800 vaccinated Israeli healthcare professionals from December 2020 to July 2021, according to survey analysis.
